Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS

The Journal of Infectious Diseases
M M BerreyLawrence Corey

Abstract

Immunologic data supporting immediate antiretroviral therapy in primary human immunodeficiency virus type 1 (HIV-1) infection are emerging; however, clinical benefit has not been demonstrated. The clinical and virologic course of 47 patients who were enrolled from September 1993 through June 1996 and who were not initially treated with potent therapy was compared with the course of 20 patients who immediately began therapy with zidovudine, lamivudine, and indinavir. Demographic and baseline laboratory data were comparable. During 78 weeks of follow-up, the early-treatment cohort showed a reduced frequency of opportunistic infections (5% vs. 21.3%; relative risk, 0.11; P=.02), less frequent progression to AIDS (13% vs. 0%), and significantly less frequent nonopportunistic mucocutaneous disorders and respiratory infections (P<.01). Plasma HIV-1 RNA levels were <50 copies/mL in all patients who continued therapy; however, after 9--12 months, HIV-1 remained detectable in latently infected CD4(+) T cells and in lymph node mononuclear cells. Combination antiretroviral therapy during primary HIV-1 infection demonstrated a decreased frequency of minor opportunistic infections, mucocutaneous disorders, and respiratory infections and red...Continue Reading

Citations

Jan 18, 2005·Clinical Evidence·Martin Talbot
Aug 11, 2005·Current HIV/AIDS Reports·Malini Soogoor, Eric S Daar
Feb 21, 2002·Current Infectious Disease Reports·Joanne Stekler, Ann Collier
Sep 11, 2002·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Monique M R De MaatJos H Beijnen
Dec 13, 2005·Sexual Health·Don E Smith, Derek J Chan
Jun 15, 2011·The Journal of Biological Chemistry·María Rosa López-HuertasMayte Coiras
May 25, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sigall Kassutto, Eric S Rosenberg
Feb 1, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cécile GoujardUNKNOWN Agence Nationale de Recherche sur le Sida PRIMO Study Group
Jan 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Pierre TattevinChristian Michelet
Jun 30, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Bruno HoenUNKNOWN QUEST Study Group
Oct 11, 2008·AIDS Research and Human Retroviruses·Joanne SteklerRobert W Coombs
Sep 10, 2011·AIDS Research and Human Retroviruses·Koen K A Van Rompay
Jan 5, 2013·Social Work·Michael N HumblePatricia M Reeves
Nov 21, 2002·AIDS·François RouetUNKNOWN ANRS 049 Abidjan DITRAME Study Group
Nov 14, 2008·AIDS·Nikos PantazisUNKNOWN CASCADE Collaboration
Sep 17, 2004·HIV Medicine·V SchifferUNKNOWN French PRIMO Cohort Study Group
Nov 26, 2002·BMJ : British Medical Journal·P J NewtonR F Miller
Mar 6, 2002·The Journal of Clinical Investigation·G Paolo RizzardiGiuseppe Pantaleo
May 9, 2008·PLoS Medicine·Sarah Rowland-Jones, Thushan de Silva
Mar 5, 2011·PloS One·Gabriel KigenUNKNOWN USAID-Academic Model for Prevention Treatment of HIV/AIDS
Feb 27, 2003·Clinical Pharmacokinetics·Monique M R de MaatJos H Beijnen
Jan 1, 2003·Clinical Drug Investigation·Monique M R de MaatJos H Beijnen
Jan 15, 2003·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Norihiro FurusyoJun Hayashi
Jul 23, 2009·Antiviral Research·Koen K A Van Rompay
Apr 8, 2004·Journal of Clinical Pharmacy and Therapeutics·M M R de MaatJ H Beijnen
Mar 31, 2007·Journal of Virological Methods·Thoai Duong LySyria Laperche
Jan 13, 2006·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Uma MalhotraM Juliana McElrath
Nov 10, 2018·AIDS Research and Human Retroviruses·Mohan Kumar Haleyur Giri SettyIndira K Hewlett
Jan 1, 2008·Current Opinion in HIV and AIDS·Cristina CelleraiSabine Kinloch-de Loes

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.